With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products
Executive Summary
CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.
You may also be interested in...
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.
Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path
Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.
FDA Warnings Target Companies US-Wide For Selling CBD Products That Violate Federal Law
CHART: The agency sent out 15 warning letters on 25 November, citing companies in 10 states for selling unapproved and misbranded CBD drug products in the guise of dietary supplements and cosmetics.